Donor Specific Toxicity of Copanlisib Identified Using Immune-Humanized Mice

  • Start Date/Time :
  • Location : Immuno-Safety Technical Committee, Webinar

The HESI Immuno-Safety Technical Committee’s humanized mouse project hosted Kristina Howard (FDA), who presented key findings from her SOT 2024 poster entitled “Donor specific toxicity of copanlisib identified using immune-humanized mice”. Copanlisib, an FDA-approved drug for lymphoma and breast cancer therapies, is being studied for its potential combined use with checkpoint inhibitors in immune-humanized mice. Initial studies revealed minimal toxicity in most cases, but significant immune responses in one donor highlight individual variations in drug effects.

Contact Us

Health and Environmental Sciences Institute (HESI)

hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403

740 15th Street NW, Suite 600
Washington, DC 20005

Stay Informed

Sign up for our monthly e-newsletter.